Director, Global Value and Health Economics and Outcomes Research

Jazz Pharmaceuticals is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments.

Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit  for more information.

Job Description

The Director, Global Value and HEOR is a strategic and execution-oriented leadership role accountable for the global and US payer evidence strategy across marketed assets in Jazz' neurology portfolio. This role is responsible for maximizing brand potential, defending value, securing expanded access, and driving evidence generation across the post-launch lifecycle-including label expansions (sNDA/sBLA), new formulations, line extensions, and competitive market shifts.

Essential

Functions/Responsibilities
1. Lifecycle Management (LCM), Label Expansions & Indication Sequencing

• Evidence Strategy for Label Expansions:
  Lead the HEOR evidence generation strategy supporting supplemental regulatory filings (sNDA/sBLA) for new indications, line extensions, expanded patient subpopulations, and novel delivery formulations/devices.

• Phase 3b/4 Trial & Pragmatic Study Optimization:
  Partner closely with Medical Affairs, Clinical Development, and Biostatistics to embed payer-relevant comparative endpoints, patient-reported outcomes (PROs), and health-related quality of life (HRQoL) measures into Phase 3b/4 protocols, pragmatic trials, and expanded access programs.

• Indication Sequencing & Access Strategy:
  Partner with Market Access to evaluate evidence requirements across multi-indication life cycles, ensuring timely delivery of comparative effectiveness and economic evidence to accelerate access upon label expansion.

• Rare Disease Registry & Long-Term Follow-Up:
  For rare disease inline assets, collaborate on long-term prospective registries, natural history extensions, and post-authorization safety/efficacy studies (PASS/PAES) to address regulatory/HTA commitments, characterize disease progression, and mitigate data uncertainty associated with small cohorts.

2. Inline Value Defense, HTA Re-Assessments & Evidence Optimization

• Value Defense Against Market Entrants:
  Proactively identify competitive threats, standard-of-care shifts, and generic/biosimilar erosion; design and execute rapid-response comparative effectiveness, adherence, and burden-of-illness studies to defend product differentiation and access positioning.

• Collaborative HTA Re-Assessments & Renewals:
  In close partnership with the EU/INT HEOR team, co-create evidence strategies and deliver analytical packages (e.g., updated network meta-analyses [NMAs], indirect treatment comparisons [ITCs], and mature economic models) required for HTA re-evaluations, conditional reimbursement reviews, and price renegotiations across major global agencies (such as EU JCA, NICE, G-BA, HAS, CADTH).

• Converting Conditional Access to Permanent Reimbursement:
  In specialized and rare disease indications, design real-world data collection programs to fulfill post-launch evidentiary commitments and convert conditional or temporary reimbursement arrangements into permanent market access.

• Global Core Deliverable Updates:
  Direct the…